Evaluation of chemotherapeutics in a three-dimensional breast cancer model

Journal of Cancer Research and Clinical Oncology

Volumn 141, Issue 5, 2015, Pages 951-959

  Lovitt, Carrie J ^a   Shelper, Todd B ^a   Avery, Vicky M ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

3D cell culture; Breast cancer; Drug resistance; Tumor microenvironment

Indexed keywords

ANTINEOPLASTIC AGENT; EPIRUBICIN; NAVELBINE; PACLITAXEL; VINBLASTINE;

ANALOGS AND DERIVATIVES; AREA UNDER THE CURVE; BREAST NEOPLASMS; CELL PROLIFERATION; CULTURE TECHNIQUE; FEMALE; HUMAN; TREATMENT OUTCOME; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BREAST NEOPLASMS; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL PROLIFERATION; EPIRUBICIN; FEMALE; HUMANS; PACLITAXEL; TREATMENT OUTCOME; VINBLASTINE;

EID: 84931332357     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-015-1950-1     Document Type: Article

References (23)

1. Barbone D, Yang TM, Morgan JR, Gaudino G, Broaddus VC (2008) Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids. J Biol Chem 283(19):13021–13030
2. Benton G, Kleinman HK, George J, Arnaoutova I (2011) Multiple uses of basement membrane-like matrix (BME/Matrigel) in vitro and in vivo with cancer cells. Int J Cancer 128(8):1751–1757
3. Breslin S, O’Driscoll L (2013) Three-dimensional cell culture: the missing link in drug discovery. Drug Discov Today 18(5–6):240–249
4. Burdett E, Kasper FK, Mikos AG, Ludwig JA (2010) Engineering tumors: a tissue engineering perspective in cancer biology. Tissue Eng Part B Rev 16(3):351–359
5. Fallahi-Sichani M, Honarnejad S, Heiser LM, Gray JW, Sorger PK (2013) Metrics other than potency reveal systematic variation in responses to cancer drugs. Nat Chem Biol 9(11):708–714
6. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin D, Forman D, Bray F (2013) GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Accessed 16 December 2013
7. Hickman JA, Graeser R, de Hoogt R, Vidic S, Brito C, Gutekunst M, van der Kuip H (2014) Three-dimensional models of cancer for pharmacology and cancer cell biology: capturing tumor complexity in vitro/ex vivo. Biotechnol J 9(9):1115–1128
8. Huang S, Pang L (2012) Comparing statistical methods for quantifying drug sensitivity based on in vitro dose-response assays. Assay Drug Dev Technol 10(1):88–96
9. Huang C, Park CC, Hilsenbeck SG, Ward R, Rimawi MF, Wang YC, Shou J, Bissell MJ, Osborne CK, Schiff R (2011) beta1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib. Breast Cancer Res 13(4):R84
10. Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, Spellman PT, Lorenz K, Lee EH, Barcellos-Hoff MH, Petersen OW, Gray JW, Bissell MJ (2007) The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol 1(1):84–96
11. Kim JB (2005) Three-dimensional tissue culture models in cancer biology. Semin Cancer Biol 15(5):365–377
12. Lovitt CJ, Shelper TB, Avery VM (2013) Miniaturized three-dimensional cancer model for drug evaluation. Assay Drug Dev Technol 11(7):435–448
13. Lovitt CJ, Shelper TB, Avery VM (2014) Advanced cell culture techniques for cancer drug discovery. Biology 3(2):345–367
14. Marlow R, Honeth G, Lombardi S, Cariati M, Hessey S, Pipili A, Mariotti V, Buchupalli B, Foster K, Bonnet D, Grigoriadis A, Rameshwar P, Purushotham A, Tutt A, Dontu G (2013) A novel model of dormancy for bone metastatic breast cancer cells. Cancer Res 73(23):6886–6899
15. Meads MB, Gatenby RA, Dalton WS (2009) Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer 9(9):665–674
16. Muranen T, Selfors LM, Worster DT, Iwanicki MP, Song L, Morales FC, Gao S, Mills GB, Brugge JS (2012) Inhibition of PI3 K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell 21(2):227–239
17. Nicolini A, Giardino R, Carpi A, Ferrari P, Anselmi L, Colosimo S, Conte M, Fini M, Giavaresi G, Berti P, Miccoli P (2006) Metastatic breast cancer: an updating. Biomed Pharmacother 60(9):548–556
18. Nirmalanandhan VS, Duren A, Hendricks P, Vielhauer G, Sittampalam GS (2010) Activity of anticancer agents in a three-dimensional cell culture model. Assay Drug Dev Technol 27:27
19. Sethi T, Rintoul RC, Moore SM, MacKinnon AC, Salter D, Choo C, Chilvers ER, Dransfield I, Donnelly SC, Strieter R, Haslett C (1999) Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 5(6):662–668
20. Sodunke TR, Turner KK, Caldwell SA, McBride KW, Reginato MJ, Noh HM (2007) Micropatterns of Matrigel for three-dimensional epithelial cultures. Biomaterials 28(27):4006–4016
21. Vinci M, Gowan S, Boxall F, Patterson L, Zimmermann M, Court W, Lomas C, Mendiola M, Hardisson D, Eccles SA (2012) Advances in establishment and analysis of 3D tumour spheroid-based functional assays for target validation and drug evaluation. BMC Biol 10(1):29
22. Weigelt B, Lo AT, Park CC, Gray JW, Bissell MJ (2009) HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res Treat 122:35–43
23. Weigelt B, Ghajar CM, Bissell MJ (2014) The need for complex 3D culture models to unravel novel pathways and identify accurate biomarkers in breast cancer. Adv Drug Deliv Rev 69–70C:42–51